Suchergebnisse

This research was supported through Coordination Theme 1 (Health) of the European Union Seventh Framework Program (FP7), Grant agreement number HEALTH-F2-2009-223091. ; Balázs, J., Miklósi, M., Keresztény, A., Hoven, C.W., Carli, V., Wasserman, C., Hadlaczky, G., Apter, A., Bobes, J., Brunner, R., Corcoran, P., Cosman, D., Haring, C., Kahn, J.-P., Postuvan, V., Kaess, M., Varnik, A., Sarchiapone, M., Wasserman, D.

Open access funding provided by University of Innsbruck and Medical University of Innsbruck. The SEYLE project is supported by the European Union through the Seventh Framework Program (FP7), Grant agreement number HEALTHF2-2009-223091. ; Banzer, R., Haring, C., Buchheim, A., Oehler, S., Carli, V., Wasserman, C., Kaess, M., Apter, A., Balazs, J., Bobes, J., Brunner, R., Corcoran, P., Cosman, D., Hoven, C.W., Kahn, J.P., Keeley, H.S., Postuvan, V., Podlogar, T., Sisask, M., Värnik, A., Sarchiapone, M., Wasserman, D.

Wasserman D, Apter G, Baeken C, Bailey S, Balazs J, Bec C, Bienkowski P, Bobes J, Ortiz MFB, Brunn H, Bôke Ö, Camilleri N, Carpiniello B, Chihai J, Chkonia E, Courtet P, Cozman D, David M, Dom G, Esanu A, Falkai P, Flannery W, Gasparyan K, Gerlinger G, Gorwood P, Gudmundsson O, Hanon C, Heinz A, Dos Santos MJH, Hedlund A, Ismayilov F, Ismayilov N, Isometsä ET, Izakova L, Kleinberg A, Kurimay T, Reitan SK, Lecic-Tosevski D, Lehmets A, Lindberg N, Lundblad KA, Lynch G, Maddock C, Malt UF, Martin L, Martynikhin I, Maruta NO, Matthys F, Mazaliauskiene R, Mihajlovic G, Peles AM, Miklavic V, Mohr P, Ferrandis MM, Musalek M, Neznanov N, Ostorharics-Horvath G, Pajević I, Popova A, Pregelj P, Prinsen E, Rados C, Roig A, Kuzman MR, Samochowiec J, Sartorius N, Savenko Y, Skugarevsky O, Slodecki E, Soghoyan A, Stone DS, Taylor-East R, Terauds E, Tsopelas C, Tudose C, Tyano S, Vallon P, Van der Gaag RJ, Varandas P, Vavrusova L, Voloshyn P, Wancata J, Wise J, Zemishlany Z, Öncü F, Vahip S

The SEYLE project was funded by the European Union Seventh Framework Program (FP7; HEALTH-F2–2009-223091; PI, Professor D. Wasserman MD PhD, NASP). ; Gambadauro, P., Carli, V., Wasserman, C., Hadlaczky, G., Sarchiapone, M., Apter, A., Balazs, J., Bobes, J., Brunner, R., Cosman, D., Haring, C., Hoven, C.W., Iosue, M., Kaess, M., Kahn, J.P., McMahon, E., Postuvan, V., Värnik, A., Wasserman, D.

The SEYLE project was funded by the European Union Seventh Framework Program (FP7; HEALTH-F2-2009-223091). Judit Balazs was supported by the Ja´nos Bolyai Research Scholarship of the Hungarian Academy of Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ; Gambadauro, P., Carli, V., Hadlaczky, G., Sarchiapone, M., Apter, A., Balazs, J., Banzer, R., Bobes, J., Brunner, R., Cosman, D., Farkas, L., Haring, C., Hoven, C.W., Kaess, M., Kahn, J.P., McMahon, E., Postuvan, V., Sisask, M., Värnik, A., Sedivy, N.Z., Wasserman, D.

The SEYLE project was supported through Coordination Theme 1 (Health) of the European Union Seventh Framework Program (FP7), Grant Agreement No. The SEYLE project was supported through Coordination Theme 1 (Health) of the European Union Seventh Framework Program (FP7), Grant Agreement No. HEALTH-F2-2009-223091. ; Durkee, T., Carli, V., Floderus, B., Wasserman, C., Sarchiapone, M., Apter, A., Balazs, J.A., Bobes, J., Brunner, R., Corcoran, P., Cosman, D., Haring, C., Hoven, C.W., Kaess, M., Kahn, J.-P., Nemes, B., Postuvan, V., Saiz, P.A., Värnik, P., Wasserman, D.

The SEYLE project was supported through Coordination Theme 1 (Health) of the European Union Seventh Framework Programme (FP7), Grant agreement number HEALTH-F2-2009-223091 ; Kasahara-Kiritani, M., Hadlaczky, G., Westerlund, M., Carli, V., Wasserman, C., Apter, A., Balazs, J., Bobes, J., Brunner, R., McMahon, E.M., Cosman, D., Farkas, L., Haring, C., Kaess, M., Kahn, J.-P., Keeley, H., Nemes, B., Bitenc, U.M., Postuvan, V., Saiz, P., Sisask, M., Värnik, A., Sarchiapone, M., Hoven, C.W., Wasserman, D.

Coordination Theme 1 (Health) of the European Union Seventh Framework Program (FP7) [HEALTH-F2-2009-223091] ; Kaess, M., Klar, J., Kindler, J., Parzer, P., Brunner, R., Carli, V., Sarchiapone, M., Hoven, C.W., Apter, A., Balazs, J., Barzilay, S., Bobes, J., Cozman, D., Gomboc, V., Haring, C., Kahn, J.-P., Keeley, H., Meszaros, G., Musa, G.J., Postuvan, V., Saiz, P., Sisask, M., Varnik, P., Resch, F., Wasserman, D.

The SEYLE project is supported through Coordination Theme 1 (Health) of the European Union Seventh Framework Programme (FP7), Grant agreement nr HEALTH-F2-2009-223091 (.)

This work was supported by the Carlos III Institute of Health and European Fund for Regional Development (PI08/1213, PI11/01977, PI14/01900, PI08/01026, PI11/02831, PI14/01621, PI08/1161, PI16/00359, PI16/01164, PI18/00805), the Basque Foundation for Health Innovation and Research (BIOEF), the Secretaria d´Universitats I Recerca del Departament d´Economia I Coneixement (2017 SGR 1365), and R&D activities in Biomedicine, Madrid Regional Government and Structural Funds of the European Union (S2017/BMD-3740 (AGES-CM 2-CM)). ; González-Ortega, I., González-Pinto, A., Alberich, S., Echeburuá, E., Bernardo, M., Cabrera, B., Amoretti, S., Lobo, A., Arango, C., Corripio, I., Vieta, E., De La Serna, E., Rodriguez-Jimenez, R., Segarra, R., López-Ilundain, J.M., Sánchez-Torres, A.M., Cuesta, M.J., Zorrilla, I., López, P., Bioque, M., Mezquida, G., Barcones, F., De-La-Cámara, C., Parellada, M., Espliego, A., Alonso-Solís, A., Grasa, E.M., Varo, C., Montejo, L., Castro-Fornieles, J., Baeza, I., Dompablo, M., Torio, I., Zabala, A., Eguiluz, J.I., Moreno-Izco, L., Sanjuan, J., Guirado, R., Cáceres, I., Garnier, P., Contreras, F., Bobes, J., Al-Halabí, S., Usall, J., Butjosa, A., Sarró, S., Landin-Romero, R., Ibáñez, A., Selva, G.

The SEYLE project is supported by the European Union through the Seventh Framework Program (FP7), Grant agreement number HEALTH-F2-2009-223091. ; Wasserman, C., Hoven, C.W., Wasserman, D., Carli, V., Sarchiapone, M., Al-Halabí, S., Apter, A., Balazs, J., Bobes, J., Cosman, D., Farkas, L., Feldman, D., Fischer, G., Graber, N., Haring, C., Herta, D.C., Iosue, M., Kahn, J.-P., Keeley, H., Klug, K., McCarthy, J., Tubiana-Potiez, A., Varnik, A., Varnik, P., Žiberna, J., Poštuvan, V.

<i>Background:</i> A 6-month naturalistic, randomized and open-label, trial of topiramate versus naltrexone was conducted, with assessments at enrollment and after 3 and 6 months of treatment. 182 alcohol-dependent patients who had been drinking heavily during the past month were included. <i>Methods:</i>Outcome was measured using tools that assessed alcohol intake, cravings, disability, and quality of life; changes in biomarkers of alcohol intake were also used. <i>Results:</i> At the 6-month evaluation, patients taking topiramate had significantly lower scores on the OCDS (all subscales), the EuropASI (medical, alcohol, family/social, and psychiatric) and the WHO/DAS (employment/social). More patients taking topiramate remained in the abstinence group and the moderate drinking without problems group. <i>Conclusions:</i> Topiramate at a mean dose of 200 mg/day was better than naltrexone at a mean dose of 50 mg/day at reducing alcohol intake and cravings throughout the study.

The study has also been financed by the RD12/0028/0016 project, which is part of the National Plan for R,D&I (Plan Nacional de I+D+I) and co-financed by the ISCII Subdirectorate General for Evaluation and the European Regional Development Fund (ERDF). With the backing of the Secretariat for Universities and Research of the Department of Economics and Knowledge, Government of Catalunya, file number 2014SGR649

<i>Aim:</i> To evaluate the effectiveness of pregabalin as a tapering therapy on the subjective sleep quality of patients who underwent a benzodiazepine withdrawal program in routine medical practice. <i>Methods:</i> Secondary analysis of a 12-week prospective, open noncontrolled study carried out in patients who met DSM-IV-TR criteria for benzodiazepine dependence. Sleep was evaluated with the Medical Outcomes Study Sleep Scale (MOS Sleep Scale). <i>Results:</i> 282 patients were included in the analysis. Mean (±SD) pregabalin dose was 315 ± 166 mg/day at the end of the trial. We observed a significant and clinically relevant improvement in sleep outcomes at the endpoint, with a total score reduction from 55.8 ± 18.9 to 25.1 ± 18.0 at week 12 (i.e. a 55% reduction). Similar findings were apparent using the six dimensions of the MOS Sleep Scale. Moderate correlations were observed between the MOS Sleep summary index and sleep domains, and there were improvements in anxiety symptoms and disease severity. <i>Conclusions:</i> These findings suggest that pregabalin may improve subjective sleep quality in patients who underwent a benzodiazepine withdrawal program. This effect appears to be partly independent of improvements in symptoms of anxiety or withdrawal. However, controlled studies are needed to establish the magnitude of the effect of pregabalin.